About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker RCUS · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other So…
NCT05536141 · Clear Cell Renal Cell Carcinoma, Solid Tumors
Casdatifan, Cabozantinib
RCUS
Arcus Biosciences, Inc.
Phase 1Recruiting512Mar 2029Registry ↗
Nov 2, 2026Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clea…
NCT07011719 · Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear…
Casdatifan, Cabozantinib
RCUS
Arcus Biosciences, Inc.
Phase 3Recruiting720Apr 2028Registry ↗
Nov 2, 2026Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic…
NCT06608927 · Metastatic Pancreatic Ductal Adenocarcinoma
Quemliclustat, Placebo
RCUS
Arcus Biosciences, Inc.
Phase 3Active, not recruiting610Nov 30, 2030Registry ↗
Nov 2, 2026Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171 · Advanced Cancer, Advanced Malignancies
AB598, Zimberelimab
RCUS
Arcus Biosciences, Inc.
Phase 1Active, not recruiting40Sep 2027Registry ↗
Oct 26, 2026A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Partic…
NCT05329766 · Gastrointestinal Tract Malignancies
Domvanalimab, Quemliclustat
RCUS
Arcus Biosciences, Inc.
Phase 2Completed332Sep 7, 2026Registry ↗
Oct 19, 2026Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
NCT04736173 · Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung…
Domvanalimab, Zimberelimab
RCUS
Arcus Biosciences, Inc.
Phase 2Completed169Sep 17, 2026Registry ↗
Oct 9, 2026A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
NCT06120075 · Advanced Cancer
AB801, Docetaxel
RCUS
Arcus Biosciences, Inc.
Phase 1Completed29Apr 29, 2026Registry ↗
Sep 9, 2026A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Mali…
NCT04104672 · Advanced Pancreatic Cancer
AB680, Zimberelimab
RCUS
Arcus Biosciences, Inc.
Phase 1Completed196Jul 21, 2026Registry ↗
Sep 4, 2026Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus…
NCT07751250 · Healthy Participants, Hepatic Impairment
Casdatifan
RCUS
Arcus Biosciences, Inc.
Phase 1Recruiting16May 2027Registry ↗
Sep 3, 2026A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy,…
NCT05568095 · Advanced Upper Gastrointestinal Tract Adenocarcinoma
Domvanalimab, Zimberelimab
RCUS
Arcus Biosciences, Inc.
Phase 3Completed1,040Aug 28, 2026Registry ↗
Aug 25, 2026A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants
NCT07662057 · Healthy Volunteers
AB102, Placebo
RCUS
Arcus Biosciences, Inc.
Phase 1Recruiting130Dec 2026Registry ↗
Aug 13, 2026A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan…
NCT07641881 · Healthy Participants
Casdatifan
RCUS
Arcus Biosciences, Inc.
Phase 1Completed24Jul 3, 2026Registry ↗
Jun 15, 2026Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive N…
NCT04262856 · Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung…
Domvanalimab, Etrumadenant
RCUS
Arcus Biosciences, Inc.
Phase 2Completed151Jul 9, 2025Registry ↗
May 1, 2026Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-2…
NCT07364214 · Healthy Participants
Quemliclustat
RCUS
Arcus Biosciences, Inc.
Phase 1Completed8Apr 6, 2026Registry ↗
Nov 13, 2025Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
NCT06919991 · Healthy Participants
Casdatifan, Itraconazole
RCUS
Arcus Biosciences, Inc.
Phase 1Completed14Oct 18, 2025Registry ↗
Oct 20, 2025An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Comb…
NCT04660812 · Metastatic Colorectal Cancer
AB680, Etrumadenant
RCUS
Arcus Biosciences, Inc.
Phase 1/2Completed227Sep 5, 2025Registry ↗
Aug 28, 2025A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
NCT04772989 · Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC)
AB308, Zimberelimab
RCUS
Arcus Biosciences, Inc.
Phase 1Completed94Aug 25, 2025Registry ↗
Jul 22, 2025Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
NCT04381832 · Prostatic Neoplasms, Castration-Resistant, Androgen-Resista…
Etrumadenant, Zimberelimab
RCUS
Arcus Biosciences, Inc.
Phase 1/2Completed173Aug 30, 2024Registry ↗
Feb 4, 2025A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
NCT03628677 · Solid Tumor, Unspecified, Adult
Domvanalimab, Zimberelimab
RCUS
Arcus Biosciences, Inc.
Phase 1Completed75Jan 23, 2025Registry ↗
Dec 9, 2024A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
NCT03846310 · Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung…
Etrumadenant, Zimberelimab
RCUS
Arcus Biosciences, Inc.
Phase 1Completed77Nov 18, 2024Registry ↗
Oct 17, 2024A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers
NCT05999513 · Healthy Participants
casdatifan
RCUS
Arcus Biosciences, Inc.
Phase 1Completed24Oct 31, 2023Registry ↗
Oct 17, 2024Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healt…
NCT05117554 · Healthy Participants
casdatifan, Placebo
RCUS
Arcus Biosciences, Inc.
Phase 1Completed70Feb 17, 2023Registry ↗
Sep 19, 2024Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Adv…
NCT04087018 · Advanced Solid Tumors
zimberelimab
RCUS
Arcus Biosciences, Inc.
Phase 1Completed18Jun 17, 2024Registry ↗
Aug 28, 2024A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers
NCT06004921 · Cancer
AB801, Placebo
RCUS
Arcus Biosciences, Inc.
Phase 1Completed32Feb 23, 2024Registry ↗
May 24, 2024A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant…
NCT05411146 · Healthy Participants
[14C]-etrumadenant
RCUS
Arcus Biosciences, Inc.
Phase 1Completed8Jul 7, 2022Registry ↗
May 24, 2024A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Health…
NCT05277012 · Healthy Participants
Etrumadenant
RCUS
Arcus Biosciences, Inc.
Phase 1Completed24Mar 31, 2022Registry ↗
May 24, 2024A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile…
NCT05154136 · Healthy Participants
Etrumadenant, Itraconazole
RCUS
Arcus Biosciences, Inc.
Phase 1Completed20Dec 10, 2021Registry ↗
May 24, 2024A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers
NCT04575311 · Healthy Volunteers
AB680, Placebo
RCUS
Arcus Biosciences, Inc.
Phase 1Completed32Sep 22, 2021Registry ↗
May 24, 2024A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
NCT03720678 · GastroEsophageal Cancer, Colorectal Cancer
etrumadenant, mFOLFOX
RCUS
Arcus Biosciences, Inc.
Phase 1Completed44Jan 27, 2021Registry ↗
May 24, 2024A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-N…
NCT03719326 · TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Etrumadenant, IPI-549
RCUS
Arcus Biosciences, Inc.
Phase 1Completed35Jul 1, 2021Registry ↗
May 24, 2024A Study to Investigate the Safety of AB680 in Healthy Volunteers
NCT03677973 · Healthy Volunteers
AB680, Placebo
RCUS
Arcus Biosciences, Inc.
Phase 1Completed64Aug 19, 2019Registry ↗
May 24, 2024A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With…
NCT03629756 · Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the…
Etrumadenant, Zimberelimab
RCUS
Arcus Biosciences, Inc.
Phase 1Completed48Aug 18, 2021Registry ↗

32 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:44 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances